A Study Comparing of Two Different Chemotherapy Regimens, in Patients With Advanced Non-Squamous Non-Small Cell Lung Cancer
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT00606021 |
Recruitment Status :
Completed
First Posted : February 1, 2008
Results First Posted : December 26, 2011
Last Update Posted : December 26, 2011
|
- Study Details
- Tabular View
- Study Results
- Disclaimer
- How to Read a Study Record
This is a multicenter, open-label, randomized, two-arm Phase 2 study comparing pemetrexed plus best supportive care with best supportive care alone as maintenance therapy following first-line treatment with a pemetrexed-cisplatin combination in patients with advanced non-squamous non-small cell lung cancer.
A total of approximately 100 patients are planned to be enrolled, and following completion of four cycles of pemetrexed-cisplatin (Induction Phase) those patients in which disease progression has not occurred will be randomized in a 2:1 ratio to one of two treatment arms (Maintenance Phase): Arm A (pemetrexed plus best supportive care) or Arm B (best supportive care alone).
Condition or disease | Intervention/treatment | Phase |
---|---|---|
Non Small Cell Lung Cancer | Drug: pemetrexed Drug: Best Supportive Care | Phase 2 |
Study Type : | Interventional (Clinical Trial) |
Actual Enrollment : | 106 participants |
Allocation: | Randomized |
Intervention Model: | Parallel Assignment |
Masking: | None (Open Label) |
Primary Purpose: | Treatment |
Official Title: | A Randomized Phase 2 Study Comparing Pemetrexed Plus Best Supportive Care With Best Supportive Care as Maintenance, Following First-Line Treatment With Pemetrexed-Cisplatin, in Patients With Advanced Non-Squamous Non-Small Cell Lung Cancer |
Study Start Date : | January 2008 |
Actual Primary Completion Date : | December 2010 |
Actual Study Completion Date : | December 2010 |

Arm | Intervention/treatment |
---|---|
Experimental: A: Pemetrexed + Best Supportive Care
Pemetrexed: 500 milligrams per square meter (mg/m²) , intravenous (IV), Day 1 of each 21-day cycle for 6 cycles Best Supportive Care: Patients will receive best supportive care (dose, frequency, duration) as judged by their treating physician. |
Drug: pemetrexed
500 mg/m², IV, Day 1 of each 21-day cycle for 6 cycles
Other Names:
Drug: Best Supportive Care Patients will receive best supportive care (dose, frequency, duration) as judged by their treating physician. |
Active Comparator: B: Best Supportive Care
Best Supportive Care: Patients will receive best supportive care (dose, frequency, duration) as judged by their treating physician.
|
Drug: Best Supportive Care
Patients will receive best supportive care (dose, frequency, duration) as judged by their treating physician. |
- Progression Free Survival During Maintenance Phase [ Time Frame: Randomization to progression of disease (PD) or date of death from any cause up to 30.9 months ]Progression free survival is defined as the time from randomization until the date of progression of disease (PD) or death from any cause. PD was determined using Response Evaluation Criteria In Solid Tumors (RECIST) criteria. PD is ≥20% increase in sum of longest diameter of target lesions. PD in maintenance phase uses the last lesion assessment prior to randomization as the baseline assessment.
- Progression Free Survival During Overall Period (Induction Phase [IP] + Maintenance Phase [MP]) [ Time Frame: First dose of study drug during IP to PD or date of death from any cause up to 33.6 months ]Progression-free survival in overall period is defined as the time from the date of first dose of study drug during IP until the date of PD or death from any cause. PD was determined using RECIST criteria. PD is ≥20% increase in sum of longest diameter of target lesions. PD in overall period uses the screening lesion assessment prior to the induction phase as the baseline assessment.
- Overall Survival During Maintenance Phase [ Time Frame: Randomization to PD or date of death from any cause up to 31.3 months ]Overall survival in maintenance phase is defined as the time from randomization to death. Participants who were alive were censored at the last contact.
- Overall Survival During Overall Period (IP + MP) [ Time Frame: First dose of study drug during IP to PD or date of death from any cause up to 34.1 months ]Overall survival in overall period is defined as the time from first dose of study drug during IP to death. Participants who were alive were censored at the last contact.
- Number of Participants With Adverse Events (AEs) During Overall Period [ Time Frame: First dose of study drug during IP through overall study completion (up to 34.3) months ]The list of serious adverse events (SAEs) and other non-serious adverse events (AEs) are in Adverse Events Section.
- Tumor Response Rate and Disease Control Rate After Induction Phase (IP) [ Time Frame: Randomization to measured PD up to 31.4 months ]Tumor response rate (%) is the number of responders (participants with best response of CR or PR) divided by the number of participants qualified for tumor response according to RECIST criteria multiplied by 100. Disease control rate is percentage of participants with a best response of stable disease [SD], PR, or CR. CR=disappearance of all target lesions; PR=30% decrease in sum of longest diameter of target lesions; PD is≥20% increase in sum of longest diameter of target lesions. SD= neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD.

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 18 Years and older (Adult, Older Adult) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | No |
Inclusion criteria:
- You must be at least 18 years old
- You must have been diagnosed with non-squamous non-small cell lung cancer (NSCLC)
- You must have had no prior systemic anticancer therapy for lung cancer
- You must live close enough to the study doctor to be able to visit regularly for follow up
- You must have signed informed consent form indicating your willingness to take part in this study
- Your laboratory and medical history and tests must meet study requirements
Exclusion criteria:
- Treatment within the last 30 days with a drug that has not received regulatory approval for any indication at the time of study entry
- Prior radiotherapy and surgery should be completed at least 4 weeks prior to initiation of treatment
- Serious concomitant systemic disorder (e.g., active infection including human immunodeficiency virus, or unstable cardiovascular disease)
- Prior malignancy other than NSCLC, carcinoma in situ of the cervix, or nonmelanoma skin cancer unless treated at least 5 years previously with no subsequent evidence of recurrence
- Brain metastasis
- Presence of clinically significant (by physical exam) third-space fluid collections, for example, ascites or pleural effusions that cannot be controlled by drainage or other procedures prior to study entry
- Significant weight loss (greater than 10%), over the previous 6 weeks before study entry
- Concurrent administration of any other antitumor therapy
- Inability to interrupt aspirin or other non-steroidal anti-inflammatory agents for a 5-day period (8-day period for long-acting agents such as piroxicam)
- Inability or unwillingness to take folic acid, dexamethasone (or equivalent) or vitamin B12 supplementation
- Pregnancy or breast-feeding
- You are allergic to pemetrexed

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00606021
Egypt | |
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. | |
Assiut, Egypt, 0000 | |
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. | |
Cairo, Egypt, 11372 | |
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. | |
Mounofia, Egypt, 32514 | |
Lebanon | |
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. | |
Beirut, Lebanon | |
Saudi Arabia | |
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. | |
Riyadh, Saudi Arabia, 11211 |
Study Director: | Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9am to 5pm Eastern Time (UTC/GMT - 5 hours, EST) | Eli Lilly and Company |
Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Responsible Party: | Eli Lilly and Company |
ClinicalTrials.gov Identifier: | NCT00606021 |
Other Study ID Numbers: |
11839 H3E-EZ-S114 ( Other Identifier: Eli Lilly and Company ) |
First Posted: | February 1, 2008 Key Record Dates |
Results First Posted: | December 26, 2011 |
Last Update Posted: | December 26, 2011 |
Last Verified: | November 2011 |
Lung Neoplasms Carcinoma, Non-Small-Cell Lung Respiratory Tract Neoplasms Thoracic Neoplasms Neoplasms by Site Neoplasms Lung Diseases Respiratory Tract Diseases |
Carcinoma, Bronchogenic Bronchial Neoplasms Pemetrexed Antineoplastic Agents Enzyme Inhibitors Molecular Mechanisms of Pharmacological Action Folic Acid Antagonists Nucleic Acid Synthesis Inhibitors |